Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Update

Estrella Immunopharma, Inc. (NASDAQ:ESLA) was the recipient of a large increase in short interest in the month of June. As of June 30th, there was short interest totalling 17,600 shares, an increase of 60.0% from the June 15th total of 11,000 shares. Based on an average daily volume of 15,100 shares, the short-interest ratio is presently 1.2 days. Currently, 0.2% of the company’s shares are short sold.

Institutional Investors Weigh In On Estrella Immunopharma

A hedge fund recently bought a new stake in Estrella Immunopharma stock. ATW Spac Management LLC acquired a new stake in Estrella Immunopharma, Inc. (NASDAQ:ESLA) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 40,000 shares of the company’s stock, valued at approximately $44,000. ATW Spac Management LLC owned 0.11% of Estrella Immunopharma at the end of the most recent reporting period. Hedge funds and other institutional investors own 0.35% of the company’s stock.

Estrella Immunopharma Stock Up 4.4 %

ESLA stock opened at $1.42 on Friday. Estrella Immunopharma has a 12 month low of $0.81 and a 12 month high of $33.00. The company has a 50-day moving average price of $1.02 and a 200 day moving average price of $1.08.

Estrella Immunopharma (NASDAQ:ESLA) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.01) EPS for the quarter.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.